IV Therapy NAD+

NAD+ is the fastest-growing segment of the IV therapy category and the one with the most documented supply problems. In 2024 the FDA issued a safety reminder that some compounders were using cheap food-grade NAD+, intended only for oral supplements, to manufacture sterile injections, and documented adverse event reports including severe chills, violent shaking and vomiting that required medical intervention. In 2025 the FDA issued a Class I recall for NAD+ for injection manufactured by GenoGenix LLC after endotoxins were detected. This year, a 27-year-old woman died in New York after an unlicensed man inserted an IV line and administered NAD+ at a lifestyle center. The evidence picture deserves the same honesty. There is one published pharmacokinetic pilot of IV NAD+ and no outcome trials. That 2019 study found free NAD+ was largely undetectable in the bloodstream for hours, because the body metabolizes it in transit, which means the phrase "100% bioavailable" describes the route rather than what reaches your cells. A 2026 systematic review concluded that marketing confidence exceeds the outcomes-quality evidence base. None of that makes an NAD+ infusion inappropriate. It makes the surrounding questions the important ones. At T Clinics USA, NAD+ is ordered by a provider who has evaluated you, sourced through a licensed compounding pharmacy, and administered inside a medical clinic in Naples, Fort Myers or Coral Springs. Results vary by individual.